Background: Aluminium-containing phosphate binders have long been used for treatment of hyperphosphatemia in dialysis patients. Their safety became controversial in the early 1980's after reports ...

Extensive coronary artery calcification (CAC) is common in people on hemodialysis. Sevelamer, a phosphate binder that does not contain calcium, is associated with slower progression of CAC than ...

The review highlights the challenges faced by patients regarding current phosphate binders, particularly focusing on issues like high pill burdens and gastrointestinal side effects, which ...

Hyperphosphatemia is linked to increased mortality risk. Dialysis patients often face a high daily pill burden, with phosphate binders making up about 50% of the total. Nonadherence to phosphate ...

The treatment of hyperphosphatemia was intensified by the additional mealtime administration of phosphate binders, such as aluminium hydroxide and calcium carbonate. Phosphate accumulation was ...